Fuse Vectors
Jordan Turnbull is an accomplished biotechnology professional currently serving as Co-CEO, Chief Scientific Officer, and Co-Founder at Fuse Vectors since August 2022, while also working remotely from Copenhagen. With a focus on technological innovation in curative cancer therapies, Jordan previously held the position of Vice President of Research and Development at ImmuneBridge for six months in 2022. Prior roles include consulting at Venn Life Sciences, serving as a Senior Scientist in Gene Therapy at Novo Nordisk, and working as a Principal Scientist and Postdoc at Boehringer Ingelheim in oncolytic viral vector downstream processing. Jordan’s academic background includes a Master's degree in Biomedicine from University College London and participation in an MBA Exchange Programme at London Business School. Additionally, Jordan co-founded Safe & Sound Festival Services Limited and held a business development associate role at CEB.
This person is not in any teams
Fuse Vectors
At Fuse Vectors, our mission is to revolutionize AAV gene therapy development. Traditional cell-based technologies have hindered progress, posing challenges in safety, efficacy, development time, and cost. Our Cell-Free AAV technology surpasses these methods, producing safer, more effective, and cost-efficient AAV viral vectors in a fraction of the time.